2 active not recruiting, 1 recruiting. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Remigromig: new trials by email Literature Review of Remigromig trials Research Report on Remigromig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO Remigromig, Aflibercept 2.0 mg - Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO) | Phase 2 | Recruiting | EyeBiotech Ltd. | 160 | 2025-09-12 | 2026-10-20 |
| A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Remigromig, Ranibizumab - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 1054 | 2025-04-16 | 2026-10-15 |
| A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME Ranibizumab, Remigromig - Diabetic Macular Edema (DME) | Phase 2 / Phase 3 | Active not recruiting | EyeBiotech Ltd. | 984 | 2024-08-07 | 2026-10-14 |
EyeBiotech Ltd. (3)
United States (3) · Argentina (2) · Colombia (2) · Puerto Rico (2) · Australia (1) · Austria (1) · Brazil (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Japan (1)
2025 (1)